N4 Pharma Share Discussion Threads

[ic0gcds00] 03/7/2019 16:36

MMS playing games

[billthebank] 03/7/2019 09:03

Anyone done a summary on here of strengths and weaknesses here recently?

[ch1rp] 02/7/2019 11:30

30p is just where it will begin with successful trial (nuvec has already been proved to work clinically). This share is 5p because the viagra trials didn't work and when they were posted there was the usual AIM carnage. I personally feel we should be sitting around 20p awaiting the good news:)))

[cone123] 02/7/2019 11:01

Ah 10million shares issued to raise cash so 10% reduction fromAll time high 32.9p still 30p..

[cone123] 02/7/2019 10:57

Without turning this into a rampfest and looking at the chart. Would it be fair to say a successful result in the coming weeks/months could result in the share price finding a new all time high? Or has the story changed since when it was 30p odd? I personally can't find anything to suggest it has.

[dave4545] 02/7/2019 10:21

Slight overhang of stock hence it's drifting down and why you could buy size well
inside the spread.

[cone123] 02/7/2019 10:17

How do I find nex trades? What are the sells v buys like?

[cone123] 02/7/2019 10:15

What?? What's it doing over there?

[dave4545] 02/7/2019 10:13

Sorry your trade is on Nex exchange

[cone123] 02/7/2019 10:09

Which still isnt showing and they ticked the price down. All of the trades this morning are buys so I do t get how they can drop it.

[soupdragon55] 02/7/2019 09:44

RNS Number : 6811C

N4 Pharma PLC

19 June 2019

19 June 2019

N4 Pharma Plc

("N4 Pharma" or the "Company")

AGM statement

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for vaccines and cancer treatments, announces that at its annual general meeting, being held later today, Nigel Theobald, Chief Executive Officer, will provide the following update on the timings for the recently announced repeat of the in vivo work at University of Queensland ("UQ").

As previously announced, studies to date have demonstrated that Nuvec(R) consistently promotes transfection in in vitro experiments using both DNA and messenger RNA (mRNA) plasmids. The primary in vivo study conducted by UQ also demonstrated that Nuvec(R) is effective in vivo, as a measurable antibody response was achieved using Ovalbumin plasmid DNA (OVA pDNA).

Evaluation of subsequent in vivo studies conducted by other laboratories indicated that the preparation and loading of Nuvec(R) with DNA or mRNA differed to the methods used by UQ in the primary study. By returning to UQ to repeat the successful in vivo work using OVA pDNA, the Company expects to affirm the precise loading protocol and methodology and to properly document the process for successful technology transfer to other CROs and partners. This will provide the benchmark conditions to be used to evaluate the delivery of antigen by Nuvec(R) in a well characterised oncology efficacy model.

The relevant committees at UQ have now approved the commencement of the studies and, with this approval, the experiments are expected to start on 21 June 2019. UQ has advised that results are expected to be available in approximately two months. The repeat work at UQ will be monitored and recorded by N4's Head of CMC Programme Development, Dr Allan Hey.

The Board is pleased to now have greater clarity on the timing of the next UQ work and believe a properly documented protocol, by repeating the earlier successful study, will enable the Company to accelerate other studies. The Company remains well funded to achieve this objective.

The Directors of the Company are mindful that Nuvec(R) will not work first time for every application and in every experiment. There are many variables to consider in any pre-clinical experiment, such as the antigen itself, how to load it onto Nuvec(R), the dose, concentration of Nuvec(R) and injection volume and understanding how these factors can cause inconsistency is an important part of Nuvec(R)'s development. The Directors remain confident that Nuvec(R) has the potential to be an innovative and effective delivery system in the field of nucleic acid vaccines and therapeutics."

[cone123] 02/7/2019 09:43

Where was that?? I couldn't find it. I'm in for 10k now anyway. Looks promising.

[soupdragon55] 02/7/2019 09:35

The relevant committees at UQ have now approved the commencement of the studies and, with this approval, the experiments are expected to start on 21 June 2019. UQ has advised that results are expected to be available in approximately two months. The repeat work at UQ will be monitored and recorded by N4's Head of CMC Programme Development, Dr Allan Hey.

[cone123] 02/7/2019 09:03

Just running through the rns mate. Where does it say 21st of June start? Thanks.

[ch1rp] 01/7/2019 08:44

Can you feel the force ?

[ch1rp] 28/6/2019 15:07

Pushing over 5p today, will see this back to 10p in no time:)))

[ch1rp] 28/6/2019 11:20

Dave your small minded attitude will make you zilch in the long term. If you have bought in at this level, congratulate yourself that you have made a great investment and don't bother about miniscule daily fluctuations:)))

[dave4545] 28/6/2019 11:06

Selling at 4.4p and 4.51p when it was 1p higher not long ago

mm's are making their usual fortunes, if you have to sell I'd wait for next mini spike upwards then offload for a reduced loss

[ch1rp] 28/6/2019 10:54

Back to 33p and onwards to 5pounds:)))

[cudmore] 28/6/2019 10:15

ETX is where your money should be going. Up 48% yesterday and only the start.

[dave4545] 28/6/2019 10:05

Some fast buck merchants got burned there !

5.9p paid down to 4.9p bid in no time

[soupdragon55] 28/6/2019 09:45

Don't think he ever did.

[cudmore] 28/6/2019 09:44

Does Woodford still hold stock here?